In animal models of sepsis and colitis, certain NLRP3‐targeted inhibitors have shown promising anti‐inflammatory effects and the potential to prevent inflammatory diseases.[7] Our previous research demonstrated that inhibiting NF‐κB‐activated pyroptosis reduced abnormal osteoclastogenesis and alleviated osteoporosis and rheumatoid arthritis.[8] Clearly, targeting NLRP3 inflammasomes presents a promising therapeutic strategy for treating inflammatory bone loss.[9] However, the specific mechanisms by which NLRP3 inflammasomes contribute to these conditions remain to be fully elucidated. Here, NLRP3 is linked to colitis.